You are here:Home-Inhibitors & Agonists-PI3K/Akt/mTOR Pathway-mTOR

Request The Product List ofmTOR mTOR

Cat. No. Product Name CAS No. Information
PC-60555

NV-128

154447-38-8

NV-128 (LY-303511) is a novel isoflavone derivative that inhibits mTOR and promotes caspase-independent cell death; induce significant cell death in both paclitaxel-resistant and carboplatin-resistant EOC cells with GI50 of 1-5 ug/mL; significantly depresses mitochondrial function by decrease in ATP, Cox-I, and Cox-IV levels, and by increase in mitochondrial superoxide and hydrogen peroxide.

PC-60418

RapaLink-1

1887095-82-0

RapaLink-1 is a third-generation mTOR inhibitor that overcomes resistance to existing first- and second-generation inhibitors; blocks mTOR signaling of the F2108L mTOR and M2327I mTOR drug resistant mutants; RapaLink-1 is more potent mTOR inhibitor than rapamycin.

PC-45649

Seco Rapamycin sodium salt

148554-65-8

Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR.

PC-42038

PQR-620

1927857-56-4

PQR-620 (PQR620) is a novel potent and selective, brain penetrant inhibitor of mTORC1/2; displays >1000-fold selectivity towards mTOR over PI3Kα in enzymatic binding assays; demonstrates inhibition of protein kinase B (pSer473) and ribosomal protein S6 (pSer235/236) phosphorylation with IC50 of 0.2 uM and 0.1 uM, respectively; shows anti-tumor effects in vitro and in vivo.

PC-35518

ICSN3250 hydrochloride

1561902-79-1 ICSN3250 (ICSN-3250) hydrochloride is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors; ICSN3250 is not a kinase inhibitor of mTOR, competes with and displaces phosphatidic acid from the FRB domain in mTOR, thus preventing mTOR activation and leading to cytotoxicity; displays no inhibitory capacity towards PI3Kα, β, γ, or δ; inhibits mTORC1 by following an unprecedented mechanism that involved its competition with PA at the FRB domain of mTOR to overcome the TSC negative regulation of mTORC1; ICSN3250 specifically targets cancer cells both in vitro and ex vivo.
PC-35517

ICSN3250

1561902-73-5 ICSN3250 (ICSN-3250) is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors; ICSN3250 is not a kinase inhibitor of mTOR, competes with and displaces phosphatidic acid from the FRB domain in mTOR, thus preventing mTOR activation and leading to cytotoxicity; displays no inhibitory capacity towards PI3Kα, β, γ, or δ; inhibits mTORC1 by following an unprecedented mechanism that involved its competition with PA at the FRB domain of mTOR to overcome the TSC negative regulation of mTORC1; ICSN3250 specifically targets cancer cells both in vitro and ex vivo.
PC-35070

Seco Rapamycin

147438-27-5 Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com